Hematological Biomarkers for Gastric Cancer Treatment Response, 2021-2024

Xinglong Lu published a dataset of 246 locally advanced gastric cancer patients who received neoadjuvant immunochemotherapy at The First Hospital of Lanzhou University between 2021 and 2024. The data includes hematological parameters measured before and after treatment, used to predict major pathologic response. The dataset was last updated on 2026-05-25.

Use Cases

• Predicting pathologic response to neoadjuvant immunochemotherapy based on pre-treatment neutrophil count.
• Identifying risk factors for incomplete pathologic response based on post-treatment platelet count.
• Optimizing treatment cycle length for patients with low pre-treatment neutrophil levels.
• Building classification models to distinguish between major and incomplete pathologic response groups.

Strengths

• Includes data from 246 consecutively enrolled patients.
• Contains a chemotherapy-alone control cohort of 147 patients for comparison.
• Specific predictive cutoffs are provided, such as a pre-treatment neutrophil count of 3.39×10⁹/L.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the main dataset is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single hospital in Lanzhou.

Provenance

Source

The First Hospital of Lanzhou University

Collection Method

Retrospective study of consecutively enrolled patients.

Time Range

2021-2024

Freshness

Last updated 2026-05-25 05:30:51; freshness should be verified.

Geography

Lanzhou, China